- Home
- SJT vs MOLN Comparison
SJT vs MOLN Comparison
Compare SJT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SJT | MOLN |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Switzerland |
| Employees | 495 | 134 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 115.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SJT | MOLN |
|---|---|---|
| Price | $3.97 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | ★ 247.3K | 1.7K |
| Earning Date | 11-24-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.37 | $3.00 |
| 52 Week High | $6.55 | $5.36 |
Technical Indicators
Market Signals| Indicator | SJT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.61 | 28.42 |
| Support Level | $2.72 | N/A |
| Resistance Level | $3.92 | $4.21 |
| Average True Range (ATR) | 0.32 | 0.11 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 59.54 | 9.27 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.